Recent advances in stroke therapy

Adrian Goldszmidt, Robert J. Wityk

Research output: Contribution to journalArticle

Abstract

Advances in stroke therapy have followed diverse paths over the past 2 years. Recent clinical trials have investigated the use of thrombolytic agents, anticoagulants, antiplatelet drugs and neuroprotective agents in acute stroke patients. The positive results of the National Institutes of Neurologic Disease and Stroke tissue plasminogen activator trial have increased interest in the field of acute stroke therapy and initiated significant changes in the management of stroke patients in the medical system. A new antiplatelet drug and a number of trials involving HMG Co-A reductase inhibitors are important advances in the secondary prevention of stroke.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalCurrent Opinion in Neurology
Volume11
Issue number1
DOIs
StatePublished - 1998

Fingerprint

Stroke
Platelet Aggregation Inhibitors
Therapeutics
Fibrinolytic Agents
Neuroprotective Agents
Tissue Plasminogen Activator
Secondary Prevention
Nervous System Diseases
Anticoagulants
Oxidoreductases
Clinical Trials

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Recent advances in stroke therapy. / Goldszmidt, Adrian; Wityk, Robert J.

In: Current Opinion in Neurology, Vol. 11, No. 1, 1998, p. 57-64.

Research output: Contribution to journalArticle

Goldszmidt, Adrian ; Wityk, Robert J. / Recent advances in stroke therapy. In: Current Opinion in Neurology. 1998 ; Vol. 11, No. 1. pp. 57-64.
@article{5b3dcd5c8bf3440d994247affb9aa4be,
title = "Recent advances in stroke therapy",
abstract = "Advances in stroke therapy have followed diverse paths over the past 2 years. Recent clinical trials have investigated the use of thrombolytic agents, anticoagulants, antiplatelet drugs and neuroprotective agents in acute stroke patients. The positive results of the National Institutes of Neurologic Disease and Stroke tissue plasminogen activator trial have increased interest in the field of acute stroke therapy and initiated significant changes in the management of stroke patients in the medical system. A new antiplatelet drug and a number of trials involving HMG Co-A reductase inhibitors are important advances in the secondary prevention of stroke.",
author = "Adrian Goldszmidt and Wityk, {Robert J.}",
year = "1998",
doi = "10.1097/00019052-199802000-00010",
language = "English (US)",
volume = "11",
pages = "57--64",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Recent advances in stroke therapy

AU - Goldszmidt, Adrian

AU - Wityk, Robert J.

PY - 1998

Y1 - 1998

N2 - Advances in stroke therapy have followed diverse paths over the past 2 years. Recent clinical trials have investigated the use of thrombolytic agents, anticoagulants, antiplatelet drugs and neuroprotective agents in acute stroke patients. The positive results of the National Institutes of Neurologic Disease and Stroke tissue plasminogen activator trial have increased interest in the field of acute stroke therapy and initiated significant changes in the management of stroke patients in the medical system. A new antiplatelet drug and a number of trials involving HMG Co-A reductase inhibitors are important advances in the secondary prevention of stroke.

AB - Advances in stroke therapy have followed diverse paths over the past 2 years. Recent clinical trials have investigated the use of thrombolytic agents, anticoagulants, antiplatelet drugs and neuroprotective agents in acute stroke patients. The positive results of the National Institutes of Neurologic Disease and Stroke tissue plasminogen activator trial have increased interest in the field of acute stroke therapy and initiated significant changes in the management of stroke patients in the medical system. A new antiplatelet drug and a number of trials involving HMG Co-A reductase inhibitors are important advances in the secondary prevention of stroke.

UR - http://www.scopus.com/inward/record.url?scp=0031983348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031983348&partnerID=8YFLogxK

U2 - 10.1097/00019052-199802000-00010

DO - 10.1097/00019052-199802000-00010

M3 - Article

C2 - 9484618

AN - SCOPUS:0031983348

VL - 11

SP - 57

EP - 64

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 1

ER -